Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

BACKGROUND: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death, causing about 750000 deaths worldwide every year. Patients with advanced hepatocellular carcinoma will often only receive transcatheter arterial chemoembolization (TACE). Glypican-3 (GPC3) is one of the most promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zheng, Wang, Jing, Li, Li, Liu, Rong, Fang, Jin, Tie, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457095/
https://www.ncbi.nlm.nih.gov/pubmed/32913856
http://dx.doi.org/10.12998/wjcc.v8.i16.3493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457095/
https://www.ncbi.nlm.nih.gov/pubmed/32913856
http://dx.doi.org/10.12998/wjcc.v8.i16.3493

Ejemplares similares